Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cevipabulin SCHEMBL4484813 | 1.00 | MBOAT4 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4477222 | 1.00 | MBOAT4 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4047501 | 0.99 | MBOAT4 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL5755942 | 0.99 | MBOAT4 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4488773 | 0.98 | MBOAT4 (0.33) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| SCHEMBL4489209 | 0.97 | MBOAT4 (0.33) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| SCHEMBL4483077 | 0.97 | MBOAT4 (0.33) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| SCHEMBL4480772 | 0.97 | MBOAT4 (0.33) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4216639 | 0.94 | ENPP1 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4211390 | 0.94 | ENPP1 (0.34) | MBOAT4ALDH1A1POLBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-2027126-A2 | CRYSTALLINE FORMS OF 5-CHLORO-6- (2, 6-DIFLUORO-4-[3- (METHYLAMINO) PROPOXY] PHENYL)-N-((1S)-2, 2, 2,-TRIFLUORO-1-METHYLETHYL][1,2,4]TRIAZOLO [1,5-A]PYRIMIDIN-7-AMINE SALTS | Wyeth Holdings Corporation (US) | 2009-02-25 | — | — | EP | claimed |
| US-7419982-B2 | Crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts | WYETH HOLDINGS CORPORATION (US) | 2008-09-02 | — | — | US | claimed |
| WO-2007136692-A2 | CRYSTALLINE FORMS OF 5-CHLORO-6- (2, 6-DIFLUORO-4- [3- (METHYLAMINO) PROPOXY] PHENYL)-N-((1S)-2, 2, 2,-TRIFLUORO-1-METHYLETHYL] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDIN-7-AMINE SALTS | WYETH HOLDINGS CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
| US-20070060597-A1 | Crystalline forms of 5-Chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts | WYETH (US) | 2007-03-15 | — | — | US | claimed |
| EP-1680425-B1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2007-01-10 | — | — | EP | claimed |
| EP-1680425-A1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-04-28 | — | — | US | claimed |
| WO-2005030775-A1 | 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | claimed |
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY INC (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025262337-A1 | METHODS AND KITS FOR IDENTIFYING NEUROLOGICAL DISEASES AND CONDITIONS | GLX ANALYTIX APS (DK) | 2025-12-26 | — | — | WO | disclosed |
| EP-4653442-A1 | POLYCYCLIC COMPOUND FOR TREATING NEUROLOGICAL DISEASES AND TUMORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| EP-4583982-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | Cardiff Oncology, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-1692137-A1 | PROCESS FOR THE PREPARATION OF TUBULIN INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1680425-A1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005056560-A1 | PROCESS FOR THE PREPARATION OF TUBULIN INHIBITORS | WYETH (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050124635-A1 | Process for the preparation of tubulin inhibitors | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005030775-A1 | 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK4, PLK2 | MBOAT4 2747/4885ALDH1A1 4432/4885POLB 773/4885 |
| US-20050124635-A1 | Process for the preparation of tubulin inhibitors | TUBB3, TUBA3C, TUBAL3 | MBOAT4 4871/4885ALDH1A1 2954/4885POLB 316/4885 |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | ABCC1, ABCB1, TUBB6 | MBOAT4 4305/4885ALDH1A1 1838/4885POLB 1330/4885 |
| US-20070060597-A1 | Crystalline forms of 5-Chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts | HCCS, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MBOAT4 4671/4885ALDH1A1 971/4885POLB 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.